Home Immunology & Inflammation CXCR antagonist Balixafortide (POL6326)

research use only

Balixafortide (POL6326) CXCR antagonist

Cat.No.S9725

An orally bioavailable peptidic CXC chemokine receptor 4 (CXCR4) antagonist, Balixafortide (POL6326) is a compound of interest in this context.

Balixafortide (POL6326) CXCR antagonist Chemical Structure

Chemical Structure

Molecular Weight: 1864.11

Jump to

Quality Control

Batch: S972501 Water]100 mg/mL]false]]]false]]]false Purity: 98.69%
98.69

Solubility

In vitro
Batch:

Water : 100 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1864.11 Formula

C84H118N24O21S2

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1051366-32-5 -- Storage of Stock Solutions

Synonyms N/A Smiles CC1NNC(CC2=CN=C[NH]2)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(CCCCN)C(=O)NC(CCC(N)=O)C(=O)NC(CC6=CC=C(O)C=C6)C(=O)NC7CSSCC(NC1=O)C(=O)NC(CO)C(=O)NC(C)C(=O)N8CCCC8C(=O)NC(CCN)C(=O)NC(CCCNC(N)=N)C(=O)C(=O)C(CC9=CC=C(O)C=C9)NC7=O

Mechanism of Action

Targets/IC50/Ki
CXCR4
In vivo

In a porcine closed-chest model of reperfused acute MI, Balixafortide (POL6326) enhances systolic function. It mobilizes Treg cells, enhances Treg cell recruitment to the infarct, attenuates tumor necrosis factor expression in monocytes and macrophages in the infarcted region, enhances infarct border-zone capillarization, reduces infarct scar size, and attenuates LV remodeling and systolic dysfunction in mice.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04826016 Withdrawn
Advanced Breast Cancer
MedSIR
 March 16 2022 Phase 1|Phase 2
NCT01905475 Completed
Large Reperfused ST-Elevation Myocardial Infarction
Polyphor Ltd.
 July 2013 Phase 2
NCT01837095 Completed
Metastatic Breast Cancer
Polyphor Ltd.
 June 2013 Phase 1
NCT01841476 Completed
Healthy
Polyphor Ltd.
 February 2012 Phase 1
NCT01105403 Completed
Multiple Myeloma
Polyphor Ltd.
 April 2009 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map